BioSante's BioVant gives 100% protection from H1N1 challenge

Illinois, USA-based BioSante Pharmaceuticals has presented H1N1 vaccine results at the Immunotherapeutics & Vaccine Summit in Providence showing that its vaccine adjuvant, BioVant, increased the protective effect of vaccines for multiple flu strains, including a potential new vaccine against H1N1 (swine flu), which resulted in 100% protection from symptoms of illness, including weight loss, and death in animal studies.

The BioSante presentation, 'BioVant Calcium Phosphate (CaP) Nanoparticles: An Effective & Safe Adjuvant for Influenza Vaccines including H1N1 and H5N1,' showed that BioVant-adjuvant effectively enhanced the natural immune response to the swine flu, using a BioVant-adjuvanted matrix protein M1 vaccine, and to H5N1 (bird flu), using a BioVant-adjuvanted H5N1 vaccine delivered via intranasal administration.

The studies concluded that swine and bird flu vaccines using BioVant may allow for availability of a greater number of lower-dose vaccines, due to its dose sparing characteristics, and intranasal administration could provide more convenient and wider distribution during a flu pandemic.